QQ客服 官方微博 反馈留言

	Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence
	Chen, Wei[1]; Xiao, Weikai[2]; Zhang, Kunsong[1]; Yin, Xiaoyu[1]; Lai, Jiaming[1]; Liang, Lijian[1]; Chen, Dong[1]
刊名	SCIENTIFIC REPORTS
	2016
卷号	6页码:000-000
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/2196750
专题	华南理工大学
作者单位	1.[1]Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pancreaticobiliary Surg, Guangzhou 510080, Guangdong, Peoples R China 2.[2]Sun Yat Sen Univ, Dept Breast Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China
推荐引用方式 GB/T 7714	Chen, Wei[1],Xiao, Weikai[2],Zhang, Kunsong[1],et al. Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence[J]. SCIENTIFIC REPORTS,2016,6:000-000.
APA	Chen, Wei[1].,Xiao, Weikai[2].,Zhang, Kunsong[1].,Yin, Xiaoyu[1].,Lai, Jiaming[1].,...&Chen, Dong[1].(2016).Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence.SCIENTIFIC REPORTS,6,000-000.
MLA	Chen, Wei[1],et al."Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence".SCIENTIFIC REPORTS 6(2016):000-000.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。